Skip to main content
. 2017 Oct 12;12(10):e0186013. doi: 10.1371/journal.pone.0186013

Fig 3. Prevalence of high platelet reactivity over time in STEMI and NSTEMI patients.

Fig 3

Proportion of patients with high platelet reactivity assessed with (A) the VASP assay and Multiplate (B) at baseline, and at 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, and 12 h after administration of a 180 mg ticagrelor loading dose in patients with STEMI and NSTEMI. HPR: high platelet reactivity, NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction, VASP: vasodilator-stimulated phosphoprotein.